1433 related articles for article (PubMed ID: 34375308)
1. Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.
Duerr R; Dimartino D; Marier C; Zappile P; Wang G; Lighter J; Elbel B; Troxel AB; Heguy A
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34375308
[TBL] [Abstract][Full Text] [Related]
2. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
[TBL] [Abstract][Full Text] [Related]
3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
4. Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections.
Ahmad L
Front Immunol; 2021; 12():742167. PubMed ID: 34804022
[TBL] [Abstract][Full Text] [Related]
5. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
[TBL] [Abstract][Full Text] [Related]
6. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
7. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.
McCallum M; Walls AC; Sprouse KR; Bowen JE; Rosen LE; Dang HV; De Marco A; Franko N; Tilles SW; Logue J; Miranda MC; Ahlrichs M; Carter L; Snell G; Pizzuto MS; Chu HY; Van Voorhis WC; Corti D; Veesler D
Science; 2021 Dec; 374(6575):1621-1626. PubMed ID: 34751595
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
Hacisuleyman E; Hale C; Saito Y; Blachere NE; Bergh M; Conlon EG; Schaefer-Babajew DJ; DaSilva J; Muecksch F; Gaebler C; Lifton R; Nussenzweig MC; Hatziioannou T; Bieniasz PD; Darnell RB
N Engl J Med; 2021 Jun; 384(23):2212-2218. PubMed ID: 33882219
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
12. Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada.
Fibke CD; Joffres Y; Tyson JR; Colijn C; Janjua NZ; Fjell C; Prystajecky N; Jassem A; Sbihi H
Front Public Health; 2022; 10():915363. PubMed ID: 35859775
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
Gillot C; Tré-Hardy M; Cupaiolo R; Blairon L; Wilmet A; Beukinga I; Dogné JM; Douxfils J; Favresse J
Virology; 2024 Jul; 595():110082. PubMed ID: 38636363
[TBL] [Abstract][Full Text] [Related]
15. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
16. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
Front Immunol; 2022; 13():801522. PubMed ID: 35222380
[TBL] [Abstract][Full Text] [Related]
17. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
Wahid M; Jawed A; Mandal RK; Dailah HG; Janahi EM; Dhama K; Somvanshi P; Haque S
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5857-5864. PubMed ID: 34604978
[TBL] [Abstract][Full Text] [Related]
18. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
[TBL] [Abstract][Full Text] [Related]
19. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
Zhou Z; Zhu Y; Chu M
Front Immunol; 2022; 13():898192. PubMed ID: 35669787
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
